EHS
EHS

STAT Plus: PhRMA responds to Trump blueprint with its own drug-pricing proposal: Reduce payments to PBMs

WASHINGTON — The drug manufacturing industry’s main lobbying group is backing a big change to the way prescription drugs are priced, but it’s unclear how it would impact the industry’s business model.

At first glance, it looked like PhRMA is embracing one of the Trump administration’s biggest ideas for addressing prescription drug prices — eliminating rebates that drug makers pay to pharmacy benefit managers, the middlemen that negotiate drug prices on behalf of insurance companies. But in fact, PhRMA’s idea is vague enough that it’s unclear exactly what it would do and whether it will bring down the price of drugs for patients.

Continue to STAT Plus to read the full story…

EHS
Back to top button